Subject(s)
Basal Cell Nevus Syndrome/pathology , Carcinoma, Basal Cell/pathology , Focal Dermal Hypoplasia/pathology , Hypotrichosis/pathology , Skin Neoplasms/pathology , Skin/pathology , Adolescent , Adult , Atrophy/pathology , Basal Cell Nevus Syndrome/diagnosis , Basal Cell Nevus Syndrome/genetics , Biopsy, Needle , Carcinoma, Basal Cell/diagnosis , Carcinoma, Basal Cell/genetics , Dermoscopy/methods , Female , Focal Dermal Hypoplasia/diagnosis , Follow-Up Studies , Genetic Predisposition to Disease , Humans , Hypotrichosis/diagnosis , Hypotrichosis/genetics , Immunohistochemistry , Male , Pedigree , Rare Diseases , Skin Neoplasms/diagnosis , Skin Neoplasms/genetics , SyndromeABSTRACT
"We are beginning to move away from clinicopathologic diagnosis into an era of clinicoimaging diagnosis." This vision became a fact, as the dermatoscope represents nowadays the dermatologist stethoscope. This is not only because dermoscopy reveals a new and fascinating morphologic dimension of pigmented and nonpigmented skin tumors, but also because it improves the recognition of a growing number of skin symptoms in general dermatology. Melanoma detection remains the most important indication of dermoscopy and in melanoma screening the aim of dermoscopy is to maximize early detection while minimizing the unnecessary excision of benign skin tumors. In the last few years, 3 meta-analyses and 2 randomized studies have definitely proven that dermoscopy allows improving sensitivity for melanoma as compared to the naked eye examination alone. This is the consequence of at least 3 issues: first, the presence of early dermoscopy signs that are visible in melanoma much before the appearance of the classical clinical features; second, an increased attitude of clinicians to check more closely clinically banal-looking lesions; third, an improved attitude of clinicians to monitor their patients.
